Alnylam pharmaceuticals reports second quarter 2020 results

Alnylam pharmaceuticals reports second quarter 2020 financial results and highlights recent period activity.alnylam pharmaceuticals - increased midpoint of guidance range for 2020 onpattro revenue, narrowing range from $270-$300 million to $280-$300 million.qtrly net product revenues $77.5 million versus $38.2 million.qtrly gaap net loss per common share - basic and diluted $1.56.qtrly non-gaap net loss per common share - basic and diluted $1.67.q2 earnings per share view $-1.74, revenue view $99.5 million -- refinitiv ibes data.
ALNY Ratings Summary
ALNY Quant Ranking